; (ii) the cost of raw materials, the cost of energy, and related costs; (iii) taxes and other incentives; and (iv) the effects of regulations; and (B) the costs and consequences of implementing, or failing to implement, each such recommendation. (d) Input The agreement under subsection (a) shall require— (1) consideration of input from the Department of Health and Human Services, the Department of Commerce, and, as appropriate, other Federal agencies; and (2) consultation with relevant stakeholders, which— (A) may include conducting public meetings and other forms of engagement, as appropriate; (B) shall include consultation with experts in— (i) the manufacturing of drugs; (ii) pharmaceutical industry business and economics; (iii) drug purchasing, pricing, and reimbursement; (iv) regulatory and intellectual property issues affecting drug manufacturing; (v) economics; (vi) international trade policy; and (vii) emergency planning; and (C) may include consultation with other entities with experience in drug manufacturing and pricing, as appropriate. (e) Definitions In this section, the term drug has the meaning given such term in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 ).